The molecular classification of medulloblastoma: Driving the next generation clinical trials

Current Opinion in Pediatrics

Volumn 24, Issue 1, 2012, Pages 33-39

  Leary, Sarah E S ^a,b,c   Olson, James M ^a,b,c  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

brain tumor; gene expression profiling; medulloblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

BIOLOGICAL THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONSENSUS DEVELOPMENT; DIAGNOSTIC IMAGING; GENOME ANALYSIS; HUMAN; MEDULLOBLASTOMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; PROGNOSIS; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84856120371     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32834ec106     Document Type: Review

References (74)

1. Central Brain Tumor Registry of the United States Statistical Report: primary brain tumors diagnosed in the United States 2004-2007. 2011:23. http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3- 3-2011.pdf
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 2007; 114:97-109. (Pubitemid 47103521)
3. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003; 39:60-67. (Pubitemid 36829097)
4. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415:436-442. (Pubitemid 34100955)
5. Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005; 23:7152-7160.
6. Palmer SL, Goloubeva O, Reddick WE, et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J Clin Oncol 2001; 19:2302-2308. (Pubitemid 32366983)
7. Lefkowitz IB, Packer RJ, Siegel KR, et al. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Cancer 1990; 65:412-417.
8. Pizer B, Donachie PH, Robinson K, et al. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study. Eur J Cancer 2011; 47:1389-1397.
9. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202-4208. (Pubitemid 46622300)
10. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): longterm results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813-820. (Pubitemid 44464063)
11. Polkinghorn WR, Dunkel IJ, Souweidane MM, et al. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys 2011; 81:e15-e20.
12. Douglas JG, Barker JL, Ellenbogen RG, Geyer JR. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 2004; 58:1161-1164. (Pubitemid 38314800)
13. Brodin NP, Rosenschold PM, Aznar MC, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol 2011; 50:806-816.
14. Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev 2009; 35:79-96.
15. Merchant TE, Hua CH, Shukla H, et al. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 2008; 51:110-117. (Pubitemid 351717400)
16. Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008; 87: 133-141.
17. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621-7631. (Pubitemid 46291826)
18. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6:573-580. (Pubitemid 41051935)
19. Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010; 28:4961-4968.
20. Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with nonmetastatic medulloblastoma treated with chemotherapy on the 'Head Start' I and II protocols. Pediatr Blood Cancer 2008; 50:1169-1175. (Pubitemid 351555540)
21. Thorarinsdottir HK, Rood B, Kamani N, et al.Outcome for children (Pubitemid 46238517)
22. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668-1671. (Pubitemid 26200029)
23. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841-851. (Pubitemid 26192135)
24. Smyth I, Narang MA, Evans T, et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 1999; 8:291-297. (Pubitemid 29054270)
25. Pastorino L, Ghiorzo P, Nasti S, et al. Identification of a SUFU germline mutation in a family with Gorlin syndrome. Am J Med Genet A 2009; 149A:1539-1543.
26. Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol 2009; 24:1526-1535.
27. Hatton BA, Villavicencio EH, Tsuchiya KD, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 2008; 68:1768-1776. (Pubitemid 351416562)
28. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001; 61:513-516. (Pubitemid 32128609)
29. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468:1095-1099. This article describes the first genetically engineered mouse model of the WNT subtype of medulloblastoma. The creation of this model and comparative description of the precise location of human WNT subtype medulloblastoma in comparison with SHH subtype medulloblastoma suggests that the molecular subtypes of medulloblastoma arise from distinct cells of origin.
30. Wasson JC, Saylors RL 3rd, Zeltzer P, et al. Oncogene amplification in pediatric brain tumors. Cancer Res 1990; 50:2987-2990. (Pubitemid 20170750)
31. Bigner SH, Friedman HS, Vogelstein B, et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990; 50:2347-2350. (Pubitemid 20134493)
32. Siu IM, Lal A, Blankenship JR, et al. c-Myc promoter activation in medulloblastoma. Cancer Res 2003; 63:4773-4776. (Pubitemid 37022603)
33. Bruggers CS, Tai KF, Murdock T, et al. Expression of the c-Myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 1998; 20:18-25. (Pubitemid 28119751)
34. Badiali M, Pession A, Basso G, et al. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 1991; 77:118-121.
35. Giangaspero F, Rigobello L, Badiali M, et al. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992; 16:687-693.
36. Brown HG, Kepner JL, Perlman EJ, et al. 'Large cell/anaplastic' medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 2000; 59:857-865.
37. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002; 126:540-544. (Pubitemid 34477948)
38. Herms J, Neidt I, Luscher B, et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000; 89:395-402.
39. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/ medulloblastoma. Clin Cancer Res 2001; 7:2425-2433. (Pubitemid 32751645)
40. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004; 63:441-449. (Pubitemid 38669665)
41. Lamont JM, McManamy CS, Pearson AD, et al. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004; 10:5482-5493. (Pubitemid 39100486)
42. Grotzer MA, von Hoff K, von Bueren AO, et al. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91: implications for investigating childhood medulloblastoma. Klin Padiatr 2007; 219:312-317. (Pubitemid 350244522)
43. de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res 2008; 14:4154-4160.
44. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24:1924-1931. (Pubitemid 46638992)
45. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PloS One 2008; 3:e3088.
46. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414. This article describes gene expression and copy number analysis of a large cohort of medulloblastoma tumors. Standard immunohistochemical markers are evaluated for the potential to establish a reliable method to rapidly identify tumors by molecular subtype.
47. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011; 121:381-396.
48. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331:435-439. This article describes whole genome sequencing of a cohort of medulloblastoma tumors. A comparison between the genetic alterations found in medulloblastoma and previously sequenced adult malignancies gives insight into the fundamental molecular differences between adult and pediatric malignancy.
49. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424-1430. This article describes gene expression and copy number analysis of a large cohort of medulloblastoma tumors with focus on differentiation between the most clinically relevant subtypes, including the WNT subtype with excellent prognosis and the MYC-activated subtype with dismal prognosis.
50. Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011; 29:2717-2723. This article describes expression analysis of adult medulloblastoma patients and demonstrates distinct differences between molecular subtypes that occur in adult versus pediatric age groups.
51. Fattet S, Haberler C, Legoix P, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 2009; 218:86-94.
52. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011; 29:1400-1407. This article describes the practical addition of molecular markers to current clinical and pathologic criteria to improve risk stratification for patients withmedulloblastoma.
53. Politi K, Pao W. How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol 2011; 29:2273-2281.
54. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461:614-620.
55. Rutkowski S, Gerber NU, von Hoff K, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro-oncol 2009; 11:201-210.
56. Leary SE, Zhou T, Holmes E, et al. Histology predicts a favorable outcome in young children with desmoplastic medulloblastoma: a report from the children's oncology group. Cancer 2011; 117:3262-3267.
57. Korshunov A, Remke M, Werft W, et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010; 28:3054-3060.
58. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28:5321-5326.
59. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-917.
60. Li H, Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 2004; 324:860-867. (Pubitemid 39345594)
61. Nakamura M, Matsuo T, Stauffer J, et al. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ 2003; 10:230-239. (Pubitemid 36553465)
62. Akinyeke TO, Stewart LV. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgamma-independent mechanism. Cancer Biol Ther 2011; 11:1046-1058.
63. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature Genet 2009; 41:465-472.
64. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006; 79:259-270. (Pubitemid 44363729)
65. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 2010; 28:3623-3629.
66. Schwalbe EC, Lindsey JC, Straughton D, et al. Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 2011; 17:1883-1894. This article describes the utility of an mRNA expression signature rather than whole genome expression to identify molecular subgroups of medulloblastoma.
67. Tamayo P, Cho YJ, Tsherniak A, et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol 2011; 29:1415-1423. This article demonstrates the marked improvement in clinical risk stratification facilitated by the addition of genomic subtyping to standard clinical criteria.
68. Reis PP, Waldron L, Goswami RS, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011; 11:46.
69. Yu L, Baxter PA, Zhao X, et al. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro-oncol 2011; 13:14-27.
70. Jakacki RI. Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Review of the literature. J Neurosurg 2005; 102:44-52. (Pubitemid 44955009)
71. Reddy AT, Janss AJ, Phillips PC, et al. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 2000; 88:2189-2193. (Pubitemid 30233223)
72. Johnston DL, Keene DL, Lafay-Cousin L, et al. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. J Neurooncol 2008; 86:101-108. (Pubitemid 350263439)
73. Li MH, Bouffet E, Hawkins CE, et al. Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurg Focus 2005; 19:E3.
74. Li M, Lee KF, Lu Y, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell 2009; 16:533-546.